Content area
Full Text
The European Medicines Agency's CHMP Pharmacovigilance Working Party held a plenary meeting from 18-20 January 2010. The following safety concerns were covered in the meeting and published in the agency's monthly report.
* The Working Party contributed to the third revision of the Core Summary of Product Characteristics (SmPC) for hormone replacement therapy (HRT) products...